ITCI - Intra-Cellular Therapies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.96
0.00 (0.00%)
As of 12:28PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close8.96
Open9.03
Bid8.97 x 800
Ask8.99 x 3000
Day's Range8.90 - 9.13
52 Week Range7.41 - 23.62
Volume146,816
Avg. Volume1,133,261
Market Cap494.352M
Beta (3Y Monthly)1.24
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 5 Biggest New Drug Approvals Potentially on the Way in 2019
    Motley Fool

    5 Biggest New Drug Approvals Potentially on the Way in 2019

    FDA approvals for these drugs could translate to billions of dollars for a few companies.

  • Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded
    Zacks

    Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded

    Key highlights of the past week include earnings update, collaborations and other pipeline news.

  • Why PulteGroup, Intra-Cellular Therapies, and Clear Channel Outdoor Slumped Today
    Motley Fool

    Why PulteGroup, Intra-Cellular Therapies, and Clear Channel Outdoor Slumped Today

    Bad news in several forms hit some stocks despite a strong session for the overall market.

  • Is Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Potentially Underrated?
    Simply Wall St.

    Is Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Potentially Underrated?

    Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a company with exceptional fundamental characteristics. Upon building...

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For July 9, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Soliton, Inc. (NASDAQ: SOLY ) shares were ...

  • Company News For Jul 9, 2019
    Zacks

    Company News For Jul 9, 2019

    Companies in the news are: AZZ, ITCI, DB and CTST

  • Intra-Cellular Therapies' Candidate Fails in Phase III Study
    Zacks

    Intra-Cellular Therapies' Candidate Fails in Phase III Study

    Intra-Cellular Therapies' (ITCI) lead candidate fails to meet primary endpoint in one of the phase III studies evaluating it in bipolar depression patients. Shares fall.

  • Why Intra-Cellular Therapies Is Tanking Today
    Motley Fool

    Why Intra-Cellular Therapies Is Tanking Today

    Investors disliked the biotech's bad news a lot more than they liked its good news.

  • MarketWatch

    Intra-Cellular Therapies stock down 15% after disappointing Phase 3 trial results

    Shares of biotech Intra-Cellular Therapies fell 15% in premarket trade Monday after the company announced disappointing results from a late-stage trial of its lead drug candidate lumateperone, a potential bipolar depression treatment. The trial, which evaluated 554 patients with bipolar disorder in the U.S., showed that lumateperone was no better than a placebo in helping to relieve symptoms of depression in patients with bipolar disorder. However, Intra-Cellular also announced positive results in a separate global trial of the drug looking at 381 patients with bipolar disorder from around the world. This Phase 3 trial met its primary endpoint; after six weeks of treatment, patients on the drug showed statistically-significant improvement over those on placebo. Intra-Cellular is also conducting a third trial of the drug, looking at it as an adjunctive therapy to lithium or valproate. In early July, Ritu Baral of Cowen said Intra-Cellular would need two positive trials to support filing a new drug application, or NDA. If both the U.S. and global trials looking at lumateperone showed positive results, the company would be able to file an NDA sometime in the second half of 2019, she wrote in a note to clients last week. But if only one of the trials was positive, the company would have to wait for data from the third trial -- evaluating lumateperone as an adjunctive therapy -- to come out. That data won't be available until 2020, she wrote. Shares of Intra-Cellular have gained 18.2% in the year to date through Friday, while the S&P 500 has gained 19.3%.

  • Benzinga

    Intra-Celluar Therapies Falls Following Results For Treatment Of Bipolar Depression

    Intra-Cellular Therapies (NASDAQ: ITCI ) shares resumed trading after the company released mixed study results from two Phase 3 clinical trials evaluating lumateperone as monotherapy in the treatment of ...

  • Reuters

    UPDATE 1-Intra-Cellular drug fails one of two bipolar depression studies; shares fall

    Intra-Cellular Therapies Inc said on Monday its lead drug failed to meet the main goal of one of two late-stage studies in patients with major depressive episodes associated with bipolar disorder. The company's shares fell 6.5% before the opening bell. The treatment, lumateperone, which is being studied as a monotherapy for the condition, failed to show statistically significant improvement in the disease condition compared to placebo in the trial, the company said.

  • MarketWatch

    Intra-Cellular announces positive results in late-stage trials of treatment for bipolar depression

    Intra-Cellular Therapies Inc. on Monday reported positive results from two late-stage trials of a treatment for bipolar depression. The New York-based company said the two phase 3 trials of lumateperone met their primary endpoints. In Study 404, that goal was change from baseline at week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo. Study 404 also met its key secondary endpoint, on the Clinical Global Impression Scale for Bipolar for Severity of Illness, or CGI-BP-S. That study produced positive results for patients with Bipolar type I and Bipolar type 2. "In Study 401, lumateperone did not separate from placebo," the company said in a statement. "A high placebo response was observed in the trial." Study 404 was conducted globally, including in the U.S. and included 381 patients. Study 401 was conducted only in the U.S. and involved 554 patients. "Consistent with previous studies in schizophrenia, lumateperone was well-tolerated in both bipolar depression studies, with a favorable safety profile," said the statement. Shares were halted for the news, but have gained 18.2% in 2019, while the S&P 500 has gained 19.3%.

  • Benzinga

    The Week Ahead In Biotech: Conferences, Clinical Trial Readouts And Earnings

    Biotech stocks saw muted sentiment in the holiday-shortened week ending July 5 after a strong rebound in the later part of the previous week. Activity was light, although news on clinical trial readouts ...

  • Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?
    Zacks

    Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?

    Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.

  • Here is What Hedge Funds Think About Intra-Cellular Therapies Inc (ITCI)
    Insider Monkey

    Here is What Hedge Funds Think About Intra-Cellular Therapies Inc (ITCI)

    "Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]

  • Before You Buy Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), Consider Its Volatility
    Simply Wall St.

    Before You Buy Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), Consider Its Volatility

    If you're interested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), then you might want to consider its beta (a...

  • Implied Volatility Surging for Intra-Cellular (ITCI) Stock Options
    Zacks

    Implied Volatility Surging for Intra-Cellular (ITCI) Stock Options

    Investors need to pay close attention to Intra-Cellular (ITCI) stock based on the movements in the options market lately.

  • TheStreet.com

    2 Biotech Names See Directors Direct Cash to Their Shares

    The market suffered a sharp selloff on Monday as China announced new tariffs effective June 1 on $60 billion of imports from the U.S. That action was response to the Trump administration's decision the previous week to raise tariffs from 10% to 25% on $200 billion of imports from China after the Chinese delegation reneged on several key provisions of a new trade deal. The administration did mend fences on the trade front elsewhere to bring its full attention to bear on China. In addition, aluminum and steel tariffs on Canada were dropped.

  • Thomson Reuters StreetEvents

    Edited Transcript of ITCI earnings conference call or presentation 8-May-19 12:30pm GMT

    Q1 2019 Intra-Cellular Therapies Inc Earnings Call

  • Such Is Life: How Intra-Cellular Therapies (NASDAQ:ITCI) Shareholders Saw Their Shares Drop 57%
    Simply Wall St.

    Such Is Life: How Intra-Cellular Therapies (NASDAQ:ITCI) Shareholders Saw Their Shares Drop 57%

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Here’s What Hedge Funds Think About Intra-Cellular Therapies Inc (ITCI)
    Insider Monkey

    Here’s What Hedge Funds Think About Intra-Cellular Therapies Inc (ITCI)

    The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]

  • Intra-Cellular Therapies, Inc. (ITCI) Q1 2019 Earnings Call Transcript
    Motley Fool

    Intra-Cellular Therapies, Inc. (ITCI) Q1 2019 Earnings Call Transcript

    ITCI earnings call for the period ending March 31, 2019.

  • Associated Press

    Intra-Cellular: 1Q Earnings Snapshot

    The New York-based company said it had a loss of 63 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...